These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6785953)

  • 1. [Studies on the properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) in normal individuals (author's transl)].
    Takahashi H; Itoh M; Kobayashi I; Hattori A; Takahashi K; Sakuragawa N; Shibata A; Tsukada T
    Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):907-17. PubMed ID: 6785953
    [No Abstract]   [Full Text] [Related]  

  • 2. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII-related activities after 1-deamino-8-D-arginine vasopressin in multicentric reticulohistiocytosis.
    Taddeo U; Trotta F; Menegale G; Ballerini G
    Ric Clin Lab; 1984; 14(1):37-9. PubMed ID: 6427880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [DDAVP and its effect on factor VIII activity (author's transl)].
    Sikorová J; Vorlová Z
    Cas Lek Cesk; 1981 May; 120(18):553-6. PubMed ID: 6794913
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The position of a vasopressin derivative ("DDAVP") in the treatment of haemophilia A (author's transl)].
    Blättler W; Jacky E; Müller M; Graf M; Meili E
    Ther Umsch; 1979 Apr; 36(4):330-3. PubMed ID: 377557
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
    Vicente V; Alberca I; Mannucci PM
    Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
    [No Abstract]   [Full Text] [Related]  

  • 8. New ways to boost factor VIII in hemophilia: DDAVP for mild hemophilia A, von Willebrand's.
    Marwick C
    JAMA; 1983 Jun; 249(24):3278-9. PubMed ID: 6406692
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men.
    Prowse CV; Farrugia A; Boulton FE; Tucker J; Ludlam CA; McLaren M; Belch JJ; Prentice CR; Dawes J; MacGregor IR
    Thromb Haemost; 1984 Feb; 51(1):110-4. PubMed ID: 6426076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDAVP in uremia.
    Vicente V; Alberca I; Macias JF; Lopez Borrasca A
    Nephron; 1984; 36(2):145-6. PubMed ID: 6420716
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDAVP stimulates prostacyclin production.
    Belch JJ; Small M; McKenzie F; Hill PA; Lowe GD; McIntyre DE; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Apr; 47(2):122-3. PubMed ID: 6808693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of DDAVP on plasma levels of factor VII and XII.
    Brommer EJ; Kluft C; Bertina RM; Alderkamp GH
    Br J Haematol; 1984 May; 57(1):173-5. PubMed ID: 6426497
    [No Abstract]   [Full Text] [Related]  

  • 14. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.
    Brommer EJ; Derkx FH; Barrett-Bergshoeff MM; Schalekamp MA
    Thromb Haemost; 1984 Feb; 51(1):42-4. PubMed ID: 6426080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.
    Holmberg L; Nilsson IM; Borge L; Gunnarsson M; Sjörin E
    N Engl J Med; 1983 Oct; 309(14):816-21. PubMed ID: 6412139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of DDAVP on plasma level of factor XII.
    Nenci GG; Berrettini M; De Cunto M; Agnelli G
    Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
    Mannucci PM; Remuzzi G; Pusineri F; Lombardi R; Valsecchi C; Mecca G; Zimmerman TS
    N Engl J Med; 1983 Jan; 308(1):8-12. PubMed ID: 6401193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of arginine-8-vasopressin and 1-deamino-8-D-arginine-vasopressin on ACTH secretion in rats.
    László FA; Janáky T; Julesz J; Kárteszi M; Makara GB; Stark E
    Endocrinol Exp; 1983 Jun; 17(2):133-6. PubMed ID: 6309504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of new synthetic vasopressin 1-deamino-8-D-arginine vasopressin (DDAVP): hemostatic control of von Willebrand's disease (author's transl)].
    Kobayashi I; Takahashi H; Sanada M; Takahashi K; Hattori A; Ito M; Sakuragawa N; Shibata A; Shinada S; Tsukada T
    Rinsho Ketsueki; 1979 Apr; 20(4):364-71. PubMed ID: 312954
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of lysine-vasopressin (LVP) and 1-deamino-8-D-arginine-vasopressin (dDAVP) upon electrical potential, short-circuit current and transepithelial D.C. resistance of the frog skin.
    Bakos P; Ponec J; Lichardus B
    Gen Physiol Biophys; 1984 Aug; 3(4):297-305. PubMed ID: 6094299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.